Bristol-Myers Squibb Company

Translation Research Scientific Leader

Cambridge, MA, United States
Feb 25, 2019
Required Education
Position Type
Full time
Translation Research Scientific Leader

Cambridge, MA

Bristol-Myers Squibb R&D is a science-driven, passionate organization determined to discover, develop and deliver medicines that have the potential to transform the lives of patients and establish new standards of care in areas of high unmet need. Patients' needs and scientific discovery are our driving force. The new Bristol-Myers Squibb research site in Cambridge's Kendall Square will position our scientific team in the heart of a vibrant ecosystem of world-class science, innovation and business opportunities. Our scientists will focus on novel targets and pathways for tumors that are refractory to current Immuno-Oncology therapies. These are significant challenges that will require innovative solutions from the biopharma, biotech and academic communities.

Role / Responsibilities

We are seeking a scientific leader with broad expertise in immuno-oncology and emerging enabling technologies to join our Translational Research group in our new state-of-the-art facility. The qualified candidate is a highly motivated, interactive, and creative individual that possesses the ability to work across a highly matrixed environment to advance the translational research efforts. The candidate will play a key role in integrating the relevant translational medicine interdisciplinary teams comprising research biology, bioinformatics, histopathology and genomics, to address mechanisms of resistance to IO therapy. The candidate will also have a pivotal role in strategic decision-making to ensure maximal alignment across the organization from discovery oncology programs through to clinical trial design. To be at the forefront of elucidating and overcoming resistance to IO therapies, should encourage scientists who are passionate problem solvers and thrive on a challenge that is clinically-vital to consider this opportunity.

  • MD, PhD or MD/PhD in Immunology, or Cancer Biology, or equivalent advanced biology degree
  • Experienced scientist with 10+ years' of post-graduate research experience, with a minimum of 5 years in a translational setting
  • Minimum 5+ years' recent experience in leading scientific teams in an academic or industry setting
  • Ideally candidate will have in-depth knowledge / understanding of various mechanisms of therapeutic response and resistance to IO utilizing a diverse set of technologies and platforms to evaluate and identify novel mechanisms of resistance
  • Driven correlative clinical association studies to better characterize the molecular underpinnings of therapeutic resistance in IO patient cohorts and correlation with clinical outcome
  • A track record of independent critical thinking and scientific achievement demonstrated by first authorship in recent high impact publications
  • Exposure to cancer immunotherapy including immune-checkpoint blockade with knowledge of current therapeutic landscape is required
  • Diverse technological expertise in genomics, patient-derived models, immunology and histopathology techniques and platforms are vital for success
  • Experience in balanced experimental design, data visualization and statistical analysis are required
  • Prior role in multidisciplinary projects and teams with ability to integrate cross-functional information required
  • Experience with managing CRO relationships and collaborating with KOL's would be advantageous
  • Excellent interpersonal skills and ability to communicate, both written and oral effectively and efficiently within the BMS organization and with external partners/collaborators
  • Thrives in fast-paced, dynamic work environment, bringing a pro-active mentality to the role

We follow the science and we'll continue to invest in translational medicine research, deepen our understanding of disease biology and uncover insights about predictive biomarkers with the ultimate goal of making precision medicine a reality for more patients.